Slide 1: Q4 & FY 2025 Earnings Presentation
Q4 & FY 2025 Earnings Presentation David Beckham Co-founded IM8 Brand with $120M+ ARR on a Billion- Dollar Path
Slide 2: Executive Summary
Executive Summary • Transformational Growth Achieved record revenue of $92.4M in FY25, driven by the explosive launch of IM8, which reached $120M ARR in its first year. $92.4M +480% FY 2025 Revenue YoY Revenue Growth • Strategic Pivot Complete Successfully divested non-core assets (ACT Genomics, Eur
Slide 3: Presentation Agenda
Presentation Agenda 01 Executive Summary 04 The IM8 Growth Story with Unit Economics 02 Strategic Transformation 05 The IM8 Community 03 Financial Results 06 FY 2026 Guidance
Slide 4: Executive Summary
Executive Summary Record-breaking growth driven by IM8 and strategic transformation $92.4M $120M+ FY 2025 Revenue IM8 ARR Run-Rate based on Dec 2025 Revenue Up 480% YoY, driven by IM8 launch Fastest growing consumer health brand on record $171M 63% Total Liquidity IM8 Gross Margin for FY 2025 Cash,
Slide 5: Strategic Transformation Complete
Strategic Transformation Complete Executing a decisive pivot to become a pure-play consumer health leader 01 02 03 Divest Non-Core Assets Focus on Consumer Accelerated Growth Health Strategic divestment of ACT Genomics, Concentrating resources on high- Resulting in a leaner, faster-growing Europa an
Slide 6: Strategic Divestitures & Value Realization
Strategic Divestitures & Value Realization Unlocking shareholder value through decisive portfolio optimization October 2025 January 2026 February 2026 ACT Genomics Europa Insighta Transaction Value Transaction Value Transaction Value $72M Cash Up to $13M Stock $70M Cash Divested clinical genomics bu
Slide 7: Strong Liquidity Position
Strong Liquidity Position Robust balance sheet with $171.1M in total adjusted liquid assets as of February 15, 2026. Asset Component Amount (US$ Millions) Cash and cash equivalents $99.3 Financial assets at fair value through profit or loss $29.3 ACT Escrow $6.3 Insighta Escrow $1.0 Sub-total $135.9
Slide 8: Q4 2025 Financial Results
Q4 2025 Financial Results Metric (US$ Millions) Q4 2025 Q3 2025 QoQ Change Q4 2024 YoY Change Total Revenue $36.6M $23.6M +55% $6.6M +455% Gross Profit $21.7M $14.0M +55% $2.4M +804% Gross Margin 59.5% 59.5% N/A 37% +2,300 bps Adjusted EBITDA ($2.3M) ($2.1M) -10% ($7.6M) +70% Note: Q3 2025 figures d
Slide 9: FY 2025 Financial Results
FY 2025 Financial Results Metric (US$ Millions) FY 2025 FY 2024 YoY Change Total Revenue $92.4M $15.9M +480% Gross Profit $48.9M $9.3M +428% Gross Margin 53% 58% -500 bps Adjusted EBITDA ($13.0M) ($17.9M) +27% Note: FY 2025 revenue growth driven by the rapid scaling of IM8. Adjusted EBITDA improveme
Slide 10: FY 2025 Revenue by Business Unit
FY 2025 Revenue by Business Unit IM8 emerges as the primary growth driver with strong gross margins IM8 $60.1M ~63% Gross Margin Europa $19.3M ~1% Gross Margin (Divested) CircleDNA $12.9M ~85% Gross Margin
Slide 11: Global Reach: Revenue by Geography
Global Reach: Revenue by Geography Strong international adoption with diversified revenue streams across key markets. Top 5 Markets (FY2025) United States $23.8M 39.7% ~$60M FY2025 Revenue Canada $8.8M 14.7% United Kingdom $7.7M 12.8% 31 Countries Shipped To Australia $3.2M 5.3% Over 60% of revenue
Slide 12: The IM8 Growth Story
The IM8 Growth Story Redefining consumer health through science and influence Co-Founded by David Beckham Leveraging global icon status to build instant trust and massive brand awareness, driving unprecedented organic traffic and conversion. Science-Backed Nutrition Formulated with clinical-grade in
Slide 13: IM8 Unprecedented Growth
IM8 Unprecedented Growth $120M Annualized Run-Rate From launch to $120M ARR in just 12 months
Slide 14: Record-Breaking Growth Trajectory
Record-Breaking Growth Trajectory Unprecedented ramp to $10M Monthly Revenue by December 2025
Slide 15: Disciplined Unit Economics Across Product Portfolio
Disciplined Unit Economics Across Product Portfolio Efficiency remains consistent across core segments, proving that higher-value customer acquisition drives proportional long-term returns. Product Line AOV CAC 24m LTV* 24m LTV:CAC* Essentials $99 $119 $434 3.66x Longevity $103 $140 $451 3.23x Beckh
Slide 16: Strategic Evolution: Maximizing Cash Yield with Quarterly Subscriptions
Strategic Evolution: Maximizing Cash Yield with Quarterly Subscriptions We are intentionally deploying higher CAC to secure 2x higher upfront AOV and immediate cash recycling via quarterly prepayments. Upfront Revenue Full Prepayment Logistics Efficiency Predictable Renewal Revenue is recognized upf
Slide 17: Structural Resilience (Jan and Feb 2026)
Structural Resilience (Jan and Feb 2026) Consistent efficiency across a premium portfolio mitigates capital risk while scaling into high-value cohorts. Essentials Longevity Beckham Stack Blended AOV: ~$173 Blended AOV: ~$209 Blended AOV: ~$402 Blended CAC: ~$195 Blended CAC: ~$236 Blended CAC: ~$454
Slide 18: Predictable Recurring Revenue
Predictable Recurring Revenue Subscription-first model drives high visibility and customer retention High-Quality Revenue Stream The vast majority of revenue is recurring, providing exceptional predictability 80% and stability to the business model. Quarterly Plan Adoption New Customers Subscription
Slide 19: Strong Unit Economics Enable Confident Scaling into 2026
Strong Unit Economics Enable Confident Scaling into 2026 Our inaugural year established the baseline; our strategic evolution to quarterly plans accelerates cash flow and lifetime value. FY2025 Foundation 2026 Strategic Evolution • Established a high-efficiency baseline with • Shift to quarterly pla
Slide 20: The Genesis of IM8: The Best Choose the Best
The Genesis of IM8: The Best Choose the Best David Beckham, who has always been fortunate to have access to the best medical, nutrition, and fitness experts throughout his life, envisioned bringing that elite level of care to everyone. Together with the team at Prenetics (NASDAQ: PRE), rooted in bio
Slide 21: The World Class IM8 Scientific Advisory Board
The World Class IM8 Scientific Advisory Board Upholding the highest standards of product excellence across nutrition, medicine, and science Dr. Dawn Mussallem Dr. James L. Green Former Prof. Suzanne Devkota Dr. James DiNicolantonio Dr. Jeremy London Board Integrative Oncologist at Chief Scientist of
Slide 22: Global Icons & Brand Ambassadors
Global Icons & Brand Ambassadors Partnering with the world's best to validate efficacy and drive global awareness David Beckham Aryna Sabalenka Ollie Bearman Co-Founder World No. 1 Tennis Player Formula 1 Driver The Visionary. Provides unparalleled global brand equity and trust. The Champion. Repres
Slide 23: Aryna Sabalenka - World No 1. Tennis Superstar
Aryna Sabalenka - World No 1. Tennis Superstar IM8 Global Ambassador and Prenetics Shareholder
Slide 24: We've Gone Viral with AI – 233 Million Views and Counting
We’ve Gone Viral with AI – 233 Million Views and Counting Our AI Video Campaign feat featuring Aryna Sabalenka https://www.instagram.com/reel/DNypO-oXqPF/ IM8 ad In Times Square for 12 Months 233 Million +Views on Instagram from Sept 25 – Sept 26
Slide 25: IM8 Community Events Around the World
IM8 Community Events Around the World Miami London New York Miami Miami New York
Slide 26: 10,000+ 5 Star Customer Testimonials
10,000+ 5 Star Customer Testimonials DOWN 25 POUNDS IMPACTFUL PRODUCT BETTER SLEEP MORE REGULAR Luke Michael Mark Shari I started taking IM8 in April, and the impact I must say that IM8 has truly exceeded my Please tell the entire team that this product So far I have definitely felt more “regular” i
Slide 27: IM8 in the News
IM8 in the News « Oh, se . N's Why Your Cells ee Might Be Aging Bobby Rich 2 Darshan Shah, MD e 2) over ita
Slide 28: OFFERINGS
Slide 29: Daily Ultimate Essentials + Hydration
FOR TODAY DAILY ULTIMATE ESSENTIALS + Hydration Daily Ultimate Essentials combines 90 premium ingredients into one delicious drink. This comprehensive formula supports energy, immunity, digestion, hydration, and overall health. Each serving includes a potent mix of vitamins, minerals, antioxidants,
Slide 30: What Sets Us Apart
What Sets Us Up Apart Cost per Month (Traditional Supplement Category Daily Ultimate Essentials + Hydration Supplements) Multivitamins, Minerals & Antioxidants $35 Superfoods, Greens & Fruits $50 Immunity $20 Electrolytes $40 Adaptogens & Super Mushrooms $30 Prebiotics, Probiotics & Postbiotics $40
Slide 31: Daily Ultimate Longevity
FOR TOMORROW DAILY ULTIMATE LONGEVITY The World’s first supplement scientifically formulated to support all 12 hallmarks of aging with a revolutionary 1,100% increase in active ingredient capacity over capsules. Featuring our breakthrough 5-Complex System with therapeutic doses of premium longevity
Slide 32: What Sets Us Apart
What Sets Us Up Apart Our Standards: We uphold the highest standards for our products, using sustainable and responsibly sourced ingredients. Our formulations are free of fillers, unnecessary ingredients, artificial flavors, preservatives, and synthetic colors. All our products undergo rigorous thir
Slide 33: Our SKUs
Our SKUs DAILY ULTIMATE ESSENTIALS DAILY ULTIMATE LONGEVITY THE BECKHAM STACK Engineered for peak absorption, this comprehensive The World’s first supplement scientifically formulated to The Beckham Stack combines IM8 Daily Ultimate Essentials formula replaces the need for 16 daily supplements with
Slide 34: Key Growth Drivers for 2026
Key Growth Drivers for 2026 Strategic initiatives to achieve $180-200M FY Revenue New Marketing Channels Website and Marketing Localization New Products Engaging digital campaigns across short-form video platforms Tailored market strategies & regional expansion with cultural Innovating wellness with
Slide 35: Marketing Channel Diversification: Reducing Platform Risk & Unlocking New Audiences
Marketing Channel Diversification: Reducing Platform Risk & Unlocking New Audiences Current State Meta: 85% Google: 15% Target Expansion → YouTube (Video Content Marketing) → TikTok (Short-Form Viral Content) → AppLovin (Programmatic Advertising) Strategic Benefits Reduced platform risk • Access to
Slide 36: Global Market Localization
Global Market Localization ¢ Authentic Cultural Relevance Japan - Japanese
Slide 37: Q4 2026 Strategic Roadmap: Expanding the Portfolio
Q4 2026 Strategic Roadmap: Expanding the Portfolio Confidential Product Launches targeting new categories and premium segments. Target Launch: Q4 2026 Target Launch: Q4 2026 Project Alpha Project Beta Entering a major new health category to significantly expand our A specialized, ultra-premium formu
Slide 38: FY 2026 Financial Guidance
FY 2026 Financial Guidance Continued momentum and scaling efficiency $180M - ~300% ~60% $200M YoY Growth Gross Margin Revenue Doubling revenue scale Maintaining premium economics Driven by full-year IM8 contribution
Slide 39: We have successfully transformed Prenetics into a high-growth consumer health leader
“ We have successfully transformed Prenetics into a high- growth consumer health leader. With IM8, we are building a billion-dollar brand that enhances lives through science. Danny Yeung Chief Executive Officer & Co-Founder
Slide 40: Disclaimer
Disclaimer This presentation has been prepared by Prenetics Global Limited (“Prenetics” or the “Company”) and is provided for informational purposes only in connection with the Company’s discussion of its Q4 and FY 2025 results. This presentation should be considered together with, and not in isolat